Kintor Pharmaceutical Limited, k'hamphani ea boemo bo holimo ea biotechnology e nts'etsapele limolek'hule tse nyane tse ncha le kalafo ea bioloji, e phatlalalitse ho ngolisoa le ho nooa ha mokuli oa eona oa pele naheng ea China tekong ea eona ea bongaka ea mekhahlelo e mengata (NCT04869228) ea proxalutamide bakeng sa kalafo ea COVID-19. bakuli ba ka ntle Sepetleleng sa Boraro sa Batho sa Shenzhen naheng ea China ka la 10 Hlakola 2022.

Teko ea phase III ke boithuto bo sa reroang, bo sa boneng habeli, bo laoloang ke placebo, bo etsoang libakeng tse ngata, bo etselitsoeng ho lekola katleho le polokeho ea proxalutamide ho bakuli ba ka ntle ba banna ba COVID-19. Teko ea phase III e ngolisitse bakuli ba ka bang 200 libakeng tsa linaha tse kenyeletsang Brazil, Philippines le Malaysia. China ke e 'ngoe ea linaha tsa bohlokoa tse nkang karolo tekong ena ea libaka tse ngata, e amohetsoeng ke NMPA ea China ka la 1 Loetse, 2021. Libaka tse nkang karolo tekong ena Chaena li kenyelletsa Sepetlele sa Beijing Ditan, Sepetlele sa Botsoalle sa China-Japan, sa Boraro. People's Hospital of Shenzhen, Shanghai Public Health Clinical Center, Hangzhou Xixi Hospital, Public Health Clinical Center ea Chengdu le Sepetlele sa Bohlano sa Batho sa Suzhou.

Dr. Tong Youzhi, mothehi, Molula-setulo, le CEO oa Kintor Pharma, o ile a fana ka maikutlo, "Re rata ho leboha ka ho khetheha Mopresidente Dr. Hongzhou Lu le sehlopha sa hae Sepetleleng sa Boraro sa Batho sa Shenzhen bakeng sa ho ngolisoa ha bakuli ba pele le ho fana ka litekanyetso tsa meriana. proxalutamide's phase III teko ea tliliniki bakeng sa ho alafa bakuli ba ka ntle ba COVID-19 naheng ea China, e leng mohato oa bohlokoa haholo bakeng sa teko ena ea bongaka ea libaka tse ngata. Re tla etsa sohle se matleng a rona ho mema libaka tse ling tsa China ho kenela boithuto bona ba bohlokoa. Ntle le moo, teko ea bongaka ea bakuli ba COVID-19 (NCT05009732) e qalile ngoliso ea bakuli United States, Ukraine le Philippines, 'me hajoale e ntse e hlahloba bakuli pele ba ngolisoa libakeng tsa China. Re boetse re nts'etsapele ts'ebetso ena linaheng tse ling tse nkang karolo litekong tsa rona tsa litleleniki tsa libaka tse ngata."

SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:

Kintor Pharmaceutical Limited, k'hamphani ea boemo bo holimo ea biotechnology e nts'etsapele limolek'hule tse nyane tse ncha le kalafo ea bioloji, e phatlalalitse ho ngolisoa le ho nooa ha mokuli oa eona oa pele naheng ea China tekong ea eona ea bongaka ea mekhahlelo e mengata (NCT04869228) ea proxalutamide bakeng sa kalafo ea COVID-19. bakuli ba ka ntle Sepetleleng sa Boraro sa Batho sa Shenzhen naheng ea China ka la 10 Hlakola 2022.
Hongzhou Lu and his team in the Third People’s Hospital of Shenzhen for the first patient enrollment and dosing in proxalutamide’s phase III clinical trial for treating COVID-19 outpatients in China, which is a very important step for this multi-regional clinical trial.
Besides, the clinical trial for COVID-19 inpatients (NCT05009732) has initiated the enrollment of patients in the United States, Ukraine and the Philippines, and is currently conducting patients screening before enrollment in sites in China.